{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:09:17Z","timestamp":1790784557259,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,23]]},"DOI":"10.7759\/cureus.88617","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T21:04:14Z","timestamp":1753304654000},"source":"Crossref","is-referenced-by-count":3,"title":["A Comparative Assessment of Intraocular Pressure Changes After Aflibercept 8 mg and Faricimab-svoa Intravitreal Injections in Wet Age-Related Macular Degeneration"],"prefix":"10.7759","author":[{"given":"Panos","family":"Gartaganis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norhan","family":"Khamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Hamoud Bedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahira","family":"Driouich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Omar","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirad","family":"Abucar Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein M","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024, 331:147-57. 10.1001\/jama.2023.26074","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119591","article-title":"Current treatments for diabetic macular edema","volume":"24","author":"Tatsumi T","year":"2023","unstructured":"Tatsumi T. Current treatments for diabetic macular edema. Int J Mol Sci. 2023, 24:9591. 10.3390\/ijms24119591","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on retinal vein occlusion","volume":"12","author":"Romano F","year":"2023","unstructured":"Romano F, Lamanna F, Gabrielle PH, et al.. Update on retinal vein occlusion. Asia Pac J Ophthalmol (Phila). 2023, 12:196-210. 10.1097\/APO.0000000000000598","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0895-z","article-title":"Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade","volume":"34","author":"Adamis AP","year":"2020","unstructured":"Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020, 34:1966-72. 10.1038\/s41433-020-0895-z","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani KG","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013, 27:787-94. 10.1038\/eye.2013.107","journal-title":"Eye (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001894","article-title":"Intraocular pressure elevation following intravitreal anti-VEGF injections: short- and long-term considerations","volume":"30","author":"Levin AM","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular pressure elevation following intravitreal anti-VEGF injections: short- and long-term considerations. J Glaucoma. 2021, 30:1019-26. 10.1097\/IJG.0000000000001894","journal-title":"J Glaucoma"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.11.019","article-title":"The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology","volume":"126","author":"Hoguet A","year":"2019","unstructured":"Hoguet A, Chen PP, Junk AK, et al.. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2019, 126:611-22. 10.1016\/j.ophtha.2018.11.019","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01211-4","article-title":"Pre-filled aflibercept syringes-variability in expressed fluid volumes and a case series of transient central retinal artery occlusions","volume":"35","author":"Gallagher K","year":"2021","unstructured":"Gallagher K, Raghuram AR, Williams GS, Davies N. Pre-filled aflibercept syringes-variability in expressed fluid volumes and a case series of transient central retinal artery occlusions. Eye (Lond). 2021, 35:2899-900. 10.1038\/s41433-020-01211-4","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1295633","article-title":"Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation","volume":"10","author":"Klaas JE","year":"2023","unstructured":"Klaas JE, Bui V, Maierhofer N, Schworm B, Maier M, Priglinger SG, Siedlecki J. Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation. Front Med (Lausanne). 2023, 10:1295633. 10.3389\/fmed.2023.1295633","journal-title":"Front Med (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.08.008","article-title":"The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review","volume":"63","author":"Bracha P","year":"2018","unstructured":"Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol. 2018, 63:281-95. 10.1016\/j.survophthal.2017.08.008","journal-title":"Surv Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good TJ","year":"2011","unstructured":"Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011, 95:1111-4. 10.1136\/bjo.2010.180729","journal-title":"Br J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"19","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 19:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"23","author":"Lanzetta P","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al.. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024, 23:1141-52. 10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"23","author":"Brown DM","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al.. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024, 23:1153-63. 10.1016\/S0140-6736(23)02577-1","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000446878","article-title":"Intraocular pressure spikes after aflibercept intravitreal injections","volume":"236","author":"El Chehab H","year":"2016","unstructured":"El Chehab H, Agard E, Russo A, Boujnah Y, Dot C. Intraocular pressure spikes after aflibercept intravitreal injections. Ophthalmologica. 2016, 236:43-7. 10.1159\/000446878","journal-title":"Ophthalmologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23039-6","article-title":"Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes","volume":"12","author":"Dingerkus VL","year":"2022","unstructured":"Dingerkus VL, Somfai GM, Kinzl S, Org\u00fcl SI, Becker MD, Heussen FM. Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci Rep. 2022, 12:18136. 10.1038\/s41598-022-23039-6","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"19","author":"Wykoff CC","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al.. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022, 19:741-55. 10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0162","article-title":"Ocular rigidity in living human eyes","volume":"46","author":"Pallikaris IG","year":"2005","unstructured":"Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci. 2005, 46:409-14. 10.1167\/iovs.04-0162","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim JE","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008, 146:930-4. 10.1016\/j.ajo.2008.07.007","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S414212","article-title":"Clinical features associated with acute elevated intraocular pressure after intravitreal anti-VEGF injections","volume":"17","author":"LoBue SA","year":"2023","unstructured":"LoBue SA, Gindina S, Saba NJ, Chang T, Davis MJ, Fish S. Clinical features associated with acute elevated intraocular pressure after intravitreal anti-VEGF injections. Clin Ophthalmol. 2023, 17:1683-90. 10.2147\/OPTH.S414212","journal-title":"Clin Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363308-a-comparative-assessment-of-intraocular-pressure-changes-after-aflibercept-8-mg-and-faricimab-svoa-intravitreal-injections-in-wet-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T21:04:15Z","timestamp":1753304655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363308-a-comparative-assessment-of-intraocular-pressure-changes-after-aflibercept-8-mg-and-faricimab-svoa-intravitreal-injections-in-wet-age-related-macular-degeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.88617","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}